INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T Cell Activity Against Global SARS-CoV-2 Variants

Overview

Journal NPJ Vaccines

Date 2021 Oct 15

PMID 34650089

Citations 24

Authors

Viviane M Andrade

Aaron Christensen-Quick

Joseph Agnes

Jared Tur

Charles Reed

Richa Kalia

Idania Marrero

Dustin Elwood

Katherine Schultheis

Mansi Purwar

Emma Reuschel

Trevor McMullan

Patrick Pezzoli

Kim Kraynyak

Albert Sylvester

Mammen P Mammen

Pablo Tebas

J Joseph Kim

David B Weiner

Trevor R F Smith

Stephanie J Ramos

Laurent M Humeau

Jean D Boyer

Kate E Broderick

Affiliations

Soon will be listed here.

Abstract

Global surveillance has identified emerging SARS-CoV-2 variants of concern (VOC) associated with broadened host specificity, pathogenicity, and immune evasion to vaccine-induced immunity. Here we compared humoral and cellular responses against SARS-CoV-2 VOC in subjects immunized with the DNA vaccine, INO-4800. INO-4800 vaccination induced neutralizing antibodies against all variants tested, with reduced levels detected against B.1.351. IFNγ T cell responses were fully maintained against all variants tested.

Citing Articles

A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.

Chavda V, Yadav D, Parmar H, Brahmbhatt R, Patel B, Madhwani K Curr Top Med Chem. 2024; 24(21):1883-1916.

PMID: 38859776 DOI: 10.2174/0115680266296095240529114058.

Genetic fusion of CCL11 to antigens enhances antigenicity in nucleic acid vaccines and eradicates tumor mass through optimizing T-cell response.

Qi H, Sun Z, Gao T, Yao Y, Wang Y, Li W Mol Cancer. 2024; 23(1):46.

PMID: 38459592 PMC: 10921619. DOI: 10.1186/s12943-024-01958-4.

COVID-19 Vaccines: Where Did We Stand at the End of 2023?.

Lundstrom K Viruses. 2024; 16(2).

PMID: 38399979 PMC: 10893040. DOI: 10.3390/v16020203.

Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models.

Guimaraes L, Costa P, Ricardo Aluotto Scalzo Junior S, Athaydes Seabra Ferreira H, Braga A, de Oliveira L Nat Commun. 2024; 15(1):590.

PMID: 38238326 PMC: 10796936. DOI: 10.1038/s41467-024-44830-1.

Lipid nanoparticle-encapsulated DNA vaccine robustly induce superior immune responses to the mRNA vaccine in Syrian hamsters.

Liao H, Shen K, Yang C, Chiu F, Chiang C, Chai K Mol Ther Methods Clin Dev. 2024; 32(1):101169.

PMID: 38187094 PMC: 10767207. DOI: 10.1016/j.omtm.2023.101169.

References

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View

Wibmer C, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B . SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021; 27(4):622-625. DOI: 10.1038/s41591-021-01285-x. View

Tarke A, Sidney J, Methot N, Yu E, Zhang Y, Dan J . Impact of SARS-CoV-2 variants on the total CD4 and CD8 T cell reactivity in infected or vaccinated individuals. Cell Rep Med. 2021; 2(7):100355. PMC: 8249675. DOI: 10.1016/j.xcrm.2021.100355. View

Mahase E . Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ. 2021; 372:n296. DOI: 10.1136/bmj.n296. View

Stephenson K, Le Gars M, Sadoff J, Marit de Groot A, Heerwegh D, Truyers C . Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. 2021; 325(15):1535-1544. PMC: 7953339. DOI: 10.1001/jama.2021.3645. View

Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias C . Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021; 27(4):620-621. DOI: 10.1038/s41591-021-01270-4. View

Wang P, Casner R, Nair M, Wang M, Yu J, Cerutti G . Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 2021; 29(5):747-751.e4. PMC: 8053237. DOI: 10.1016/j.chom.2021.04.007. View

Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes C, Finkin S . mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021; 592(7855):616-622. PMC: 8503938. DOI: 10.1038/s41586-021-03324-6. View

Edupuganti S, De Rosa S, Elizaga M, Lu Y, Han X, Huang Y . Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults. Vaccines (Basel). 2020; 8(4). PMC: 7762306. DOI: 10.3390/vaccines8040741. View

10.

Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer A, Ginn H . Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021; 184(11):2939-2954.e9. PMC: 8008340. DOI: 10.1016/j.cell.2021.03.055. View

11.

Tebas P, Kraynyak K, Patel A, Maslow J, Morrow M, Sylvester A . Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. J Infect Dis. 2019; 220(3):400-410. DOI: 10.1093/infdis/jiz132. View

12.

Channappanavar R, Zhao J, Perlman S . T cell-mediated immune response to respiratory coronaviruses. Immunol Res. 2014; 59(1-3):118-28. PMC: 4125530. DOI: 10.1007/s12026-014-8534-z. View

13.

Tebas P, Yang S, Boyer J, Reuschel E, Patel A, Christensen-Quick A . Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine. 2021; 31:100689. PMC: 7759123. DOI: 10.1016/j.eclinm.2020.100689. View

14.

Sariol A, Perlman S . Lessons for COVID-19 Immunity from Other Coronavirus Infections. Immunity. 2020; 53(2):248-263. PMC: 7359787. DOI: 10.1016/j.immuni.2020.07.005. View

15.

Gallais F, Velay A, Nazon C, Wendling M, Partisani M, Sibilia J . Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France. Emerg Infect Dis. 2020; 27(1). PMC: 7774579. DOI: 10.3201/eid2701.203611. View

16.

Davies N, Abbott S, Barnard R, Jarvis C, Kucharski A, Munday J . Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021; 372(6538). PMC: 8128288. DOI: 10.1126/science.abg3055. View

17.

McMahan K, Yu J, Mercado N, Loos C, Tostanoski L, Chandrashekar A . Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2020; 590(7847):630-634. PMC: 7906955. DOI: 10.1038/s41586-020-03041-6. View

18.

Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F . Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021; 27(5):917-924. DOI: 10.1038/s41591-021-01318-5. View

19.

Davies N, Jarvis C, Edmunds W, Jewell N, Diaz-Ordaz K, Keogh R . Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021; 593(7858):270-274. PMC: 9170116. DOI: 10.1038/s41586-021-03426-1. View

20.

Smith T, Patel A, Ramos S, Elwood D, Zhu X, Yan J . Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020; 11(1):2601. PMC: 7239918. DOI: 10.1038/s41467-020-16505-0. View